AQNA-DY002: A Double-Masked, Randomized Study of the Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery
The primary objective of this study is to test the hypothesis that DYME is safe and effective as a drug to facilitate continuous curvilinear capsulorhexis (CCC) by selectively staining the anterior capsule. Secondary objectives are to compare the safety and effectiveness of DYME to that of a smaller dose of the same API.
100 Clinical Results associated with Aqumen Biopharmaceuticals KK
0 Patents (Medical) associated with Aqumen Biopharmaceuticals KK
100 Deals associated with Aqumen Biopharmaceuticals KK
100 Translational Medicine associated with Aqumen Biopharmaceuticals KK